|
|
|
International Clinical Trials
|
The 11th Annual Partnerships in Clinical Trials Congress and Exhibition
focuses on the strategic and practical approaches to improving all
partnerships between trial sponsors and their suppliers, in order to
reduce costs, improve quality and accelerate clinical development.
The conference, on the 6th-9th November 2012, in the CCH Congress
Center, Hamburg, Germany, covers the entire clinical development
pipeline for pharmaceuticals and biotech, stretching from outsourced
R&D and preclinical through to Phase 3. The key theme for this
year’s event is ‘adapting to change: minimising risk through agile
development.’ Through lively debate and in-depth discussions, the
programme will examine managing risk strategically, with a defined set
of criteria for risk-based monitoring. Other key themes include: tactics
for efficient operational delivery; critical examination of strategic
outsourcing models; and planning and measuring project success.
New additions to the 2012 programme include an expert opinion track,
including a panel discussion that will look at the impact of CROs and
other vendors going private. There will also be an initiative on
outsourcing strategies for small- and medium-pharma and biotech, with a
focussed networking opportunity for service providers to meet small- and
mediumsized pharma companies.
The economic keynote presentation from Joe Nellis, Professor of
International Management Economics, Director of Policy Strategy and
Performance Community at Cranfield University will present “a
competitive outlook for 2013 and beyond.” His take on leading change
through strategic partnerships is simple: “what new businesses, what new
alliances, what new partnerships have you not yet thought about which
might be the right structures for the future?”
In the industry keynote presentation, John Orloff, Senior Vice
President, Global Development and Chief Medical Officer, Novartis Pharma
AG, will examine “high level strategic innovations for clinical trials:
what needs to change?” This presentation will give an assessment of the
current issues and challenges that the industry faces in clinical
research.
For inspiration, Didi Hopkins, International Centre for Programme Management, Cranfield School of Management,
and Senior Trainer, The National Theatre, London, will present two
workshops at the pre-conference symposium: “gravitas, power and presence
– using the language of leadership to improve your public speaking”;
and “women in leadership forum: be seen, be heard, be taken seriously.”
Delegates will also have the opportunity to hear from the true leader of
the e-patient movement, Dave deBronkart, better known as ‘e-patient
Dave’, and learn how this empowered patient beat stage 4 cancer.
The ‘leadership’ keynote comes from Itay Talgam, Music Director of the
Tel-Aviv Symphony Orchestra and internationally renowned conductor.
Through his humorous and interactive session, ‘lead like the great
conductors: getting a brilliant performance without saying a word,’ Itay
will examine how to resist micro-management and give space for your
partners to perform.
One of the pre-conference workshops will deliver an audience with the
FDA, assessing what is expected of risk-based monitoring. This will be
presented by Ann Meeker-O’Connell, Acting Associate Director, Risk
Science, Intelligence and Prioritization, US Food and Drug
Administration, CDER. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
Stockley Park, UK – 3 November 2022 – Gilead Sciences, Inc. and
Kite, a Gilead Company, will support 30 data presentations, including
seven oral presentations in large B-cell lymphoma (LBCL) and two oral
presentations on investigator-sponsored studies in acute myeloid
leukaemia (AML), during the 64th Annual American Society of Hematology
(ASH) Annual Meeting (10-13 December).
More info >> |
|
 |
White Papers |
 |
|
Customising the Cold Chain
World Courier
Of all the statistics emerging around the global pharmaceutical industry this year, two big numbers capture the attention of both manufacturers and their logistics partners: $248 billion, the amount the “BRIC” nations (Brazil, Russia, India and China) are poised to account for in pharmaceutical sales for by 2016; and $8 billion, the amount global pharma will spend on cold chain logistics in 2014. Why are these two numbers so noteworthy? They demonstrate that as R&D goes, so goes logistics. As products evolve to meet demands for more targeted therapies, demand for more targeted logistics solutions grows as well. And that means a need for customization for everything from clinical trial samples to finished product.
More info >> |
|
|
